Neurodegeneration is the gradual degeneration of the nervous system, which leads to the deterioration of cognitive and motor functions. It can be caused by a variety of factors, such as age-related disorders, trauma, infections, toxic exposures, metabolic imbalances, and genetic mutations. Neurodegenerative diseases—including Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS)—are among the most widespread and debilitating conditions that affect elderly individuals, as well as younger populations. Symptoms of neurodegeneration can range from mild to severe, depending on the disease, and include memory loss, difficulty concentrating, impaired movement, poor coordination, and difficulty speaking. In order to effectively diagnose and treat neurodegenerative conditions, researchers must gain a better understanding of the underlying causes and mechanisms of neurodegeneration. A variety of approaches are employed in research, including investigation of genetic and molecular events associated with disease progression, the study of proteins and pathways involved in the neurodegenerative process, and the evaluation of model systems. In recent years, scientists have also used animal models to study various aspects of neurodegeneration, including its neuroprotective effects, which is the ability of certain agents or compounds to slow or prevent the deterioration of neurons. Neurodegeneration is an important area of research that has led to advancements in the understanding of the molecular mechanisms of neurodegenerative diseases. These insights can be used to identify therapeutic targets and develop novel treatments to alleviate the symptoms of neurodegenerative diseases. Despite the progress made over the past several decades, there is still much to be learned about how neurodegeneration occurs and how it can be effectively prevented and treated.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom